



\*\*\*\*\*

\*\*\* \*\* \*

Aubervilliers (93300)

\*\*\*\*\*

\*\*\*\*\*@\*\*\*\*\*.\*\*

## Attaché de Recherche Clinique, Sénior

### EXPERIENCES PROFESSIONNELLES

juil. 2022 / aujourd'hui

#### Freelance Study Coordinator

Actalent on behalf IQVIA

July 2022- Today's Freelance Study coordinator –Actalent on behalf IQVIA, Paris

-Follow-up of a phase III study in psychiatry (Schizophrenia)

- Performing site management,
- Performing data entry,
- Queries resolution,
- AE and concomitant treatment reconciliation,
- Electronic CRF.

Therapeutic area: CNS.

Site number: 1, France.

Patient number: 1.

-Follow-up of a phase III study in oncology (Lymphoma)

- Performing site management,
- Performing data entry,
- Queries resolution,
- AE and concomitant treatment reconciliation,
- Electronic CRF.

Therapeutic area: Oncology.

Site number: 2, France.

Patient number: 8.

-Follow-up of a phase I/II study in oncology (Lymphoma)

- Performing site management,
- Performing data entry,
- Queries resolution,
- AE and concomitant treatment reconciliation,
- Electronic CRF.

Therapeutic area: Oncology.

Site number: 1, France.

Patient number: 12.

mai 2022 / juin 2022

Clinical Research Associate -Euraxi Pharma, Joué Les Tours

\*Follow-up of a phase IV study in oncology (Breast cancer)

\* Performing monitoring visit.

\* Electronic CRF.

Therapeutic area: Oncology.

Site number: 2, France.

Patient number: 47.

\*Follow-up of a phase IV study in oncology (Urothelial carcinoma)

\* Performing monitoring visit.

\* Electronic CRF.

Therapeutic area: Oncology.

Site number: 5, France.

Patient number: 60.

\*Follow-up of a phase IV study in oncology (Lymphoma)

\* Performing monitoring visit.

\* Electronic CRF.

Therapeutic area: Oncology.

Site number: 1, France.

Patient number: 8.

*\*Follow-up of a phase IV study in hematology (ASMD disease)*

*\* Performing monitoring visit.*

*\* Electronic CRF.*

*Therapeutic area: Hematology.*

*Site number: 5, France.*

*Patient number: 30.*

*\*Follow-up of a phase IV study in hematology (Gaucher disease)*

*\* Performing site initiation phone call.*

*\* Electronic CRF.*

*Therapeutic area: Hematology.*

*Site number: 5, France.*

*Patient number:60.*

**juil. 2021 /**

### **Today's**

Paris

*\*Follow-up of a phase III study in diabetology.*

*\* Performing monitoring visit.*

*\* Electronic CRF.*

*Therapeutic area: Diabetology.*

*Site number: 1, France.*

*Patient number: 18.*

**juin 2021 / avr. 2022**

### **Clinical Research Associate**

ConvaTec Laboratories, La Garenne-Colombes

*\*Follow-up of an observational study in continence care*

*\* Performing site initiation visit.*

*\* Performing monitoring visit.*

*\* Regulatory submissions*

*\* Electronic CRF.*

*Therapeutic area: Urology.*

*Site number: 9, France.*

*Patient number:160.*

*\*Follow-up of an observational study in cicatrization*

*\* Performing site initiation visit*

*\* Management of the Investigators Meeting*

*\* Performing monitoring visit.*

*\* Regulatory submissions*

*\* Electronic CRF.*

*Therapeutic area: Advanced Wound Care.*

*Site number: 5, France.*

*Patient number:90.*

**févr. 2019 /**

Study coordinator - Hospital Necker

*\*Follow-up of an observational study in Alport syndrome*

*\* Performing data entry in an electronic e-CRF.*

*\* Electronic CRF.*

*Therapeutic area: Nephrology.*

*Site number: 40, France.*

*Patient number:90.*

*\*Follow-up of an observational study in cystinosis*

*\* Performing data entry in an electronic e-CRF.*

*\* Electronic CRF.*

*Therapeutic area: Nephrology.*

*Site number: 40, France.*

*Patient number:90.*

**oct. 2018 / déc. 2018**

### **Interim period - Polyvalent employee**

Alliance emploi

*\* Postal tri selection*

**déc. 2016 / févr. 2017**

### **Freelance Senior Coordinator Clinical Research Associate**

GALENUS., Basel

*\*Follow-up of a global national phase IV epilepsy study for SANOFI.*

*\* Performing On site site monitoring and close-out visits. Producing comprehensive monitoring visit and close-out reports.*

*\* Electronic CRF.*

*Therapeutic area: Epilepsy.*

*Site number: 3, France.*

*Patient number: 160.*

août 2012 / mai 2015

### Senior Coordinator Clinical Research Associate

BIOPROJET Laboratory, Paris

- \*Follow-up of an international phase III narcolepsy study.*
- \* Performing On site site monitoring and close-out visits. Producing comprehensive monitoring and close-out visit reports.*
- \* DSMB Management,*
- \* Investigator payment,*
- \* Review of the Statistical Analyses Report and clinical study report,*
- \* Regulatory submission,*
- \* Electronic CRF,*
- \* Audit followed: No major findings.*

*Therapeutic area: Central Nervous System.*  
*Site number: 8, France and Hungary.*  
*Patient number: 102.*

- \*Follow-up of an international phase II smoking cessation study.*
- \* Study start-up phase,*
- \* Regulatory submission,*
- \* DSMB management,*
- \* CRO management (Co-monitoring visits, mentoring of Junior CRA, answering to daily contact, contract management),*
- \* Preparation of the ICF, CRF, summary,*
- \* Review of the monitoring plan and the data management plan,*
- \* Electronic CRF.*

*Therapeutic area: Addictology.*  
*Site number: 19, France, Poland and Republic Czech.*  
*Patient number expected: 250*

- \*Follow-up of an international phase II cocaine cessation study.*
- \* Study start-up phase,*
- \* Regulatory submission,*
- \* DSMB management,*
- \* CRO management (Co-monitoring visits, mentoring of Junior CRA, answering to daily contact, contract management),*
- \* Preparation of the ICF, CRF, summary,*
- \* Review of the monitoring plan and the data management plan,*
- \* Electronic CRF.*

*Therapeutic area: Addictology.*  
*Site number: 3, Netherlands and Belgium.*  
*Patient number expected: 194*

- \*Follow-up of an international phase II cocaine cessation study.*
- \* Study start-up phase,*
- \* Regulatory submission,*
- \* DSMB management,*
- \* CRO management (Co-monitoring visits, mentoring of Junior CRA, answering to daily contact, contract management),*
- \* Preparation of the ICF, CRF, summary,*
- \* Review of the monitoring plan and the data management plan,*
- \* Electronic CRF.*

*Therapeutic area: Addictology.*  
*Site number: 3, United-States.*  
*Patient number expected: 250*

- \*Follow-up of an international phase II restless leg syndrome study.*
- \* Study start-up phase.*
- \* DSMB management,*
- \* CRO management (Co-monitoring visits, mentoring of Junior CRA, answering to daily contact, contract management),*
- \* Preparation of the ICF, CRF, summary,*
- \* Review of the monitoring plan and the data management plan,*
- \* Electronic CRF.*

*Therapeutic area: Central Nervous System.*  
*Site number: 3, France.*  
*Patient number expected: 91*

juil. 2012 / sept. 2015

### Freelance Senior Coordinator Clinical Research Associate

ADENOBIO N. V., Paris

- \*Follow-up of a global national phase II ischemic heart disease study.*
- \* Performing On site site monitoring and close-out visits. Producing comprehensive monitoring and close-out visit reports.*
- \* Review of the Statistical Analyses Report and clinical study report*
- \* Regulatory submission,*

\* Paper CRF.  
Therapeutic area: Cardiovascular disease.  
Site number: 1, France.  
Patient number: 60.

**déc. 2010 / juil. 2011**

**Clinical Research Associate**

CRO Quintiles, Levallois-Perret

\*Follow-up of a global national phase IV axial spondyloarthritis study for PFIZER.  
\* Performing On site site selection visits and site initiation visit. Producing comprehensive selection visit reports.  
\* Paper CRF.

Therapeutic area: Rheumatology.  
Site number: 15

\* Follow-up of a global international phase IV HIV-1 study for PFIZER.  
\* Submission to the ethic committee and the regulatory authorities. Preparation of the summary and the ICF.  
\* Performing On site site selection visit.  
\* Electronic CRF.  
Therapeutic area: Infectious diseases.  
Site number: 6

\*Follow-up of a global international phase IV neuropathic low back pain study for PFIZER.  
\* Submission to the ethic committee and the regulatory authorities. Preparation of the summary and the ICF.  
\* Performing On site site selection visit.  
\* Paper CRF.  
Therapeutic area: Rheumatology.  
Site number: 12

\*Follow-up of a global international phase IV acute myocardial infarction for PFIZER.  
\* Performing On site site initiation visit.  
\* Electronic CRF.  
Therapeutic area: Cardiovascular disease.  
Site number: 6.

\*Follow-up of a global international phase IV acute leukemia study for PFIZER.  
\* Performing On site site initiation visit.  
\* Electronic CRF.  
Therapeutic area: Oncology.  
Site number: 12.

**juin 2008 / nov. 2010**

**Clinical research associate**

CRO OmnicareCR, Gentilly

\*Follow-up of a national phase II study for SANOFI-PASTEUR  
\* On site Monitoring visits of a phase II rabies vaccination study.  
\* Collection of essential document.  
\* SAE report form checking.  
\* Queries resolution.

Therapeutic area: Immunization/vaccines.  
Site number: 3  
Patient number: 300

\* Follow-up of a national phase II study for SANOFI PASTEUR  
\* On site Site initiation and monitoring visits of a phase II A/H1N1 vaccination study.  
\* Collection of essential document.  
\* SAE report form checking.  
\* Queries resolution.  
\* Audit followed: No major findings.  
Therapeutic area: Immunization/vaccines.  
Site number: 3  
Patient number: 300

\* Follow-up of a national phase III study for SANOFI PASTEUR.  
\* On site Monitoring and close-out visits of a phase III flu vaccination study.  
\* Collection of essential document.  
\* SAE report form checking.  
\* Queries resolution.  
Therapeutic area: Immunization/vaccines.  
Site number: 3  
Patient number: 100

	<ul style="list-style-type: none"> <li>* In service at BAXTER, Maurepas (during 9 months between June 2008 and March 2009).</li> <li>* Identification of potential investigational sites,</li> <li>* On site Selection, initiation, monitoring and close-out visits of a phase III parenteral nutrition study taking part in France and in Belgium,</li> <li>* Within international, the collection of high quality critical documents and completion of ethics committee and regulatory submissions in association with Investigators Services,</li> <li>* Administrative follow-up, logistics of treatments and materials of the study,</li> <li>* Queries resolution.</li> </ul> <p>Therapeutic area: Pediatrics Gastroenterology.  Site number: 8  Patient number: 90</p>
<b>oct. 2006 /</b>	<p><b>Assistant to project leader</b>  Marc2007</p> <ul style="list-style-type: none"> <li>* Qualification of files resulting from investigations by adding knew information,</li> <li>* Proof reading to check for consistency.</li> </ul>
<b>janv. 2002 / sept. 2006</b>	<p>Salesman - Art gallery of Decorations and Antiquities, Paris</p> <ul style="list-style-type: none"> <li>* Reception of international customer,</li> <li>* Management of the store,</li> <li>* Organization of transport and storage logistics.</li> </ul>
<b>juil. 1999 / nov. 2001</b>	<p>Computer engineer - Company Transiciel, Saint-Cloud</p> <ul style="list-style-type: none"> <li>* Administration of technical plateforms « receipt and qualification »,</li> <li>* Follow-up of compilations,</li> <li>* Management of the incidents within the support team.</li> </ul> <p>In service at : Exane, ParisbourseSA-Euronext, Bouygues Télécom, GIE cartes bancaires.</p>
<b>janv. 1998 / juin 1999</b>	<p><b>Military period</b>  Institut de Recherche Criminelle de Gendarmerie Nationale - Laboratoire de microanalyse, Rosny-sous-Bois</p> <p>Activity: Participation in 4 forensics investigations using the techniques of scanning microscopy, of ICP- plasma torch spectrometry, and IR spectrometry.</p>
<b>sept. 1997 / déc. 1997</b>	<p><b>Training engineer</b>  Délégation Générale de l'Armement, Arcueil</p> <p>Mission: Study of optical and chemical characteristics of molecules presenting of the properties useful for optical limitation.</p>
<b>janv. 1995 / août 1997</b>	<p>Scientific animator - In service at : UCPA, Cité des sciences et de l'industrie, Musée de l'air et de l'espace du Bourget</p> <p>du Bourget, ANSTJ, Aloïse, Planète-sciences, Société française de chimie, Association petits débrouillards, Ateliers bleus de la ville de Paris...</p>
<b>oct. 1994 / juil. 1995</b>	<p><b>Engineer of studies</b>  ESPCI, Paris</p> <p>Master's degree training period: Study of complex of inclusion cyclodextrin - aromatic ketones substituted by solid NMR spectrometry.</p>
<b>mars 1994 / juin 1994</b>	<p>Training chemist - UPMC, Paris</p> <p>Memoir: Followed desalumination of zeolite LZY64 by solid NMR spectrometry.</p>
<b>/</b>	<p>CRO ClinicaLand, Paris</p> <ul style="list-style-type: none"> <li>* Follow-up of a national renal failure phase IV study for SHIRE.</li> <li>* On site monitoring visits and close-out visits,</li> <li>* Investigators payment,</li> <li>* Update of the administrative documents (TMF, SOP),</li> <li>* SAE report form checking.</li> <li>* Paper CRF</li> </ul> <p>Therapeutics area: nephrology  Site number: 50.  Patient number: 400.</p> <p>* Follow-up of an international phase IV study dealing with the use of a hemostatic swab</p>

in surgery for NYCOMED.

\* On site monitoring visits and close-out visits,

\* Management of investigators and hospital contract negotiation and payment,

\* Update of the administrative documents (TMF, SOP),

\* SAE report form checking.

\* Paper CRF

Therapeutics area: surgery

Site number: 50.

Patient number: 400.

\* Follow-up of a national phase III study dealing the acne treatment for URIAGE.

\* On site site selection visit, site initiation, monitoring visits and close-out visits,

\* Management of investigators and hospital contract negotiation and payment,

\* Submission to regulatory affairs and ethics committees,

\* SAE report form checking,

\* Paper CRF.

Therapeutics area: dermatology

Site number: 10.

Patient number: 120.

\* Feasibility study on a phase III study dealing with chronic obstructive bronchopneumopathy for BAYER.

\* On site pre-study visit.

\* Essential documents collection.

Therapeutics area: pneumology.

Site number: 30.

## DIPLOMES ET FORMATIONS

---

juil. 2019 / nov. 2019

**Consultant collaborative office 365 microsoft training program**

Eliadys academy-Rueil-Malmaison

/ juin 2007

**Clinical research associate training program**

April-June; Institut Léonard De Vinci - GEMS - Pôle universitaire La Défense

/ juin 1995

**DEA de chimie appliquée et genie des procedes industriels (equivalent to Master's degree in applied chemistry and industrials engineering process)**

- BAC+3

Ecole Nationale Supérieure Chimie Paris

/ juin 1990

**DEUG de sciences de la nature et de la vie (equivalent to second year of university in natural and life sciences) - BAC+2**

Faculté de Médecine de Bobigny

## COMPETENCES

---

data management plan, Computer engineer, office 365, Microsoft office, CTMS, COMPUTER TECHNOLOGY

## COMPETENCES LINGUISTIQUES

---

Anglais

## CENTRES D'INTERETS

---

Running, swimming, biking, Concert, theater, exposition